Proteomics

Mass spectrometry identifies and quantifies proteins by their mass-to-charge ratios. Affinity-based platforms (aptamers, antibodies) measure specific proteins at high throughput. Data-independent acquisition (DIA) enables comprehensive protein measurement. AI identifies diagnostic protein signatures from large cohort studies. Single-cell proteomics measures protein expression in individual cells.

Multi-protein panels detect cancer earlier than single-marker tests. Proteomic profiling identifies drug targets for therapeutic development. Companion diagnostics predict treatment response based on protein expression. Multi-omic integration combines proteomic, genomic, and clinical data for comprehensive patient characterization.

The global proteomics market exceeded $30 billion in 2025, encompassing instruments, reagents, services, and informatics. The clinical proteomics segment (diagnostics and companion diagnostics) is the fastest-growing area.